Division of Neurology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama-city, Saitama, Japan; Department of Pediatrics and Adolescent Medicine, Tokyo Medical University, 6-7-1, Nishi-shinjuku, Shinjuku-ku, Tokyo, Japan.
Division of Neurology, Saitama Children's Medical Center, 1-2 Shintoshin, Chuo-ku, Saitama-city, Saitama, Japan.
Seizure. 2021 Feb;85:6-11. doi: 10.1016/j.seizure.2020.12.008. Epub 2020 Dec 17.
We aimed to study the efficacy of adrenocorticotropic hormone (ACTH) treatment on infantile spasms with different aetiologies. In particular, we were interested in patients with structural-acquired aetiology.
Patients with infantile spasms, who were treated with ACTH, were divided into three groups based on the aetiologies: unknown aetiology with normal development (unknown-normal), structural-acquired, and combined-congenital aetiologies that included genetic, metabolic, structural-congenital, or unknown aetiology with developmental delay.
Of the 107 patients included (58 males, 49 females), 25 patients had unknown-normal aetiology [median age at onset 5 months, standard deviation (SD) 3.12, range 2-16 months]; 20 patients had structural-acquired aetiology (median age at onset 6.5 months, SD 3.85 months, range 4-17 months); and 62 patients had combined-congenital aetiologies (median age at onset 5 months, SD 2.73 months, range 2-16 months). The efficacy of ACTH was 64.0 %, 65 %, and 30.6 % in the unknown-normal aetiology, structural-acquired aetiology, and combined-congenital aetiologies, respectively (p < 0.01). Multivariate analysis showed a statistically significant higher efficacy in the unknown-normal aetiology [Odds ratio (OR) 4.63, 95 % confidence interval (CI) 1.60-13.30] and structural-acquired aetiology (OR 3.41, 95 % CI 1.01-11.50) compared to that in the combined-congenital aetiologies.
Infantile spasms with structural-acquired aetiology had greater response to ACTH treatment than those with combined-congenital aetiologies. The efficacy of standard therapy of infantile spasms should be considered based on aetiology.
我们旨在研究促肾上腺皮质激素(ACTH)治疗不同病因婴儿痉挛的疗效。特别是,我们对结构性获得性病因的患者感兴趣。
接受 ACTH 治疗的婴儿痉挛患者根据病因分为三组:病因不明但发育正常(不明-正常)、结构性获得性病因和包括遗传、代谢、结构性先天性或病因不明伴发育迟缓的混合先天性病因。
107 例患者中,25 例病因不明-正常(中位发病年龄 5 个月,标准差(SD)3.12,范围 2-16 个月);20 例结构性获得性病因(中位发病年龄 6.5 个月,SD 3.85 个月,范围 4-17 个月);62 例混合先天性病因(中位发病年龄 5 个月,SD 2.73 个月,范围 2-16 个月)。在不明-正常病因、结构性获得性病因和混合先天性病因中,ACTH 的疗效分别为 64.0%、65%和 30.6%(p<0.01)。多变量分析显示,不明-正常病因(优势比(OR)4.63,95%置信区间(CI)1.60-13.30)和结构性获得性病因(OR 3.41,95%CI 1.01-11.50)的疗效显著高于混合先天性病因。
与混合先天性病因相比,结构性获得性病因的婴儿痉挛对 ACTH 治疗的反应更大。应根据病因考虑婴儿痉挛的标准治疗疗效。